Heparin (Liquaemin)

Subscribe to Selected New Research on Heparin

15669 relevant articles (1087 outcomes, 1882 trials/studies) found for this Drug

Description: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Also Known As:

Liquaemin; Heparin Sodium; Sodium Heparin; Heparin, Sodium; alpha Heparin; Heparinic Acid; alpha-Heparin

Relationship Network

Drug Context: Research Results

Carbohydrates: 2945

Polysaccharides: 1669

Glycosaminoglycans: 2413

Heparin: 15669

Low-Molecular-Weight Heparin: 3058

Heparinoids: 306

calcium heparin: 147

BGH: 124

heparin proteoglycan: 18

Essaven Gel: 15

heparinized hydrophilic polymer: 10

Contractubex: 9

N-acetylheparin: 8

N-desulfated heparin: 7

thrombolytin: 7

IC 831423: 6

dioparin: 5

O-desulfated heparin: 5

doxorubicin-heparin: 2

heparin adipic hydrazide-cortisol: 2

RO-heparin: 2

Sportgel: 2

diabtyl: 1

folate-heparin-lithocholate: 1

silver-allantoin-heparin: 1

di-(3-(N,N-dibutylamino))propyl carbonate

fluoresceinylthiocarbamyl-heparin

Hep-HSA

heparin disaccharide

heparin-lithocholate

heparin-piracetam complex

heparin-poly(methyl methacrylate) copolymer

heparin-polyvinyl alcohol hydrogel

ITF 1175

ITF 331

low density lipoprotein-heparin complex

methyl tricaprylyl ammonium chloride-heparin complex

N-desulfated,2-O,3-O-desulfated heparin

N-propionylated heparin

poly(dimethylsiloxane)-(polyethylene oxide)-heparin copolymer

polylysine-heparin

protamine heparin aggregate

protamine-heparin membrane

PTIR-RS-1 heparin

PZ68B

Q93C-239 sulfaminoheparosan

raparin

SHPP heparin

SR 80037A

technetium Tc 99m heparin

TSKgel heparin-5PW

Vascularin-Gel

Venostatin

Experts

1.	Warkentin, Theodore E: 45 articles (10/2008 - 06/2002)
2.	Hursting, Marcie J: 27 articles (09/2008 - 03/2002)
3.	Greinacher, Andreas: 27 articles (08/2008 - 07/2002)
4.	Greinacher, A: 22 articles (09/2008 - 03/2000)
5.	Warkentin, T E: 17 articles (09/2008 - 06/2000)
6.	Antman, Elliott M: 17 articles (12/2007 - 02/2002)
7.	Walenga, Jeanine M: 16 articles (09/2008 - 01/2002)
8.	Koster, A: 16 articles (09/2007 - 02/2000)
9.	Cohen, Marc: 16 articles (09/2007 - 04/2002)
10.	Califf, Robert M: 15 articles (08/2008 - 07/2002)

Related Diseases

1.	Thrombosis (Thrombus) 04/01/2002 - "Although various types of heparin coatings were effective in reducing (sub)acute thrombosis, most of them failed to reduce neointimal proliferation. " 01/01/1999 - "Unfractionated heparin (UH), administered subcutaneously in low doses of 5000 U every 12 h, is safe and effective in preventing thrombosis in most patients. " 01/01/1994 - "In the event of a marked decrease in platelet count associated with venous or arterial thrombosis, heparin therapy should be stopped immediately. " 05/01/2002 - "With improved surgical techniques, the use of heparin-based thromboprophylactic agents has allowed significant advances in the prevention of thrombosis during the past 30 years. " 10/01/1994 - "CONCLUSION: Right atrial thrombus can be treated successfully with heparin, leading to its resolution and a normal pregnancy outcome." Order ALL the reference details at left...
2.	Venous Thrombosis (Deep-Vein Thrombosis) 09/01/1988 - "The purpose of this prospective, randomized study was to evaluate the efficacy of low-dose heparin, alone or in combination with electric stimulation, in the prevention of deep vein thrombosis (DVT) in C2 to T11 motor complete and incomplete-preserved motor, nonfunctional spinal cord injured patients. " 01/01/1991 - "Native heparin was very effective in models of arterial and venous thrombosis as well as in a model demonstrating the effect on endothelial stability in rats. " 03/01/2000 - "This study was undertaken to investigate the efficacy of delivering heparin at a high dose locally but low dose systemically (heparin infusion via a catheter placed proximal to the venous anastomosis) to prevent venous thrombosis in microsurgery. " 01/01/1984 - "Although the results are not statistically significant, this study suggests that a single dose of heparin given intravenously during operation is a safe and effective means of prophylaxis against deep-vein thrombosis in patients who undergo general surgical procedures. " 02/26/1982 - "Further studies with larger numbers of patients are required in order to show a significant reduction in the incidence of post-operative deep vein thrombosis in hip surgery patients receiving low-dose adjusted heparin." Order ALL the reference details at left...
3.	Hemorrhage 12/01/2007 - "Heparin use provides the best results but may be associated with a higher mortality rate related to intra-abdominal bleeding. " 01/01/2006 - "However, heparin therapy is not always associated with a significant improvement of clinical outcomes, is linked with enhanced bleeding risk and can occasionally provoke the development of heparin-induced thrombocytopaenia, the most devastating complication of conventional therapy with unfractioned heparin. " 08/01/2004 - "The aim of this study was to investigate whether clinically important bleeding attributable to heparin rebound can be eliminated by infusion of small amounts of additional protamine for 6 hours postoperatively and whether this treatment can reduce mediastinal blood loss. " 11/15/1994 - "APC improved the prolonged bleeding time, but heparin aggravated bleeding with potent prolongation of activated partial thromboplastin time (APTT). " 02/01/1978 - "Neither heparin's therapeutic efficacy nor its ability to increase bleeding could be proven. " Order ALL the reference details at left...
4.	Myocardial Infarction 11/01/2000 - "A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction." 03/10/2009 - "BACKGROUND: Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging. " 09/01/2001 - "The authors conclude that the use of low dose heparin appears effective and safe in cases without acute myocardial infarction. " 04/01/1990 - "SK and t-PA with or without post-thrombolytic heparin treatment appear equally effective and safe for use in routine conditions care, in all patients with acute myocardial infarction (AMI)." 11/01/1998 - "BACKGROUND: The safety and efficacy of bedside monitors of activated partial thromboplastin time (aPTT) have not been examined in a large population receiving intravenous heparin after thrombolytic treatment for acute myocardial infarction. " Order ALL the reference details at left...
5.	Thrombocytopenia (Thrombopenia) 01/01/2008 - "Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series." 07/01/2007 - "CONCLUSION: Because of its high sensitivity, we believe the PF4 ENHANCED enzyme-linked immunosorbent assay should be used to identify heparin-induced thrombocytopenia in patients with multiple potential causes of thrombocytopenia, although false-positive results will not be uncommon." 08/01/2005 - "OBJECTIVE: Heparin-induced thrombocytopenia Type II (HIT II) is the autoimmune-mediated severe form of the disease characterized by a significant reduction in platelets, and it carries a high risk of "paradoxical" serious thrombotic complications. " 04/01/1984 - "Positive results (greater than 20% aggregation) occurred in (1) five of 14 patients with heparin-associated thrombocytopenia, (2) 0 of 16 consumptive thrombocytopenic controls not given heparin therapy, (3) one of 14 nonthrombocytopenic controls given heparin, and (4) one of 13 healthy controls, giving a sensitivity of 36% and specificities of 100%, 93%, and 92%, respectively. " 05/01/1997 - "The results of a series of clinical trials reveal that LMWHs are at least as safe and effective as UFH for initial treatment, with the additional advantage of the possibility of home treatment without the requirement of laboratory control and with a reduced risk of heparin-induced thrombocytopenia. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
2.	Aspirin (Acetylsalicylic Acid)
3.	Enoxaparin (Lovenox)
4.	Thrombin
5.	Warfarin (Coumadin)
6.	bivalirudin (Angiomax)
7.	Hirudins
8.	Dalteparin (Dalteparin Sodium)
9.	Glycoproteins (Glycoprotein)
10.	argatroban (MPQA)

Related Therapies and Procedures

1.	Stents
2.	Renal Dialysis (Hemodialysis)
3.	Thrombolytic Therapy
4.	Angioplasty (Angioplasties)
5.	Hip Replacement Arthroplasty (Total Hip Replacement)

Best Treatments:
Research Summary Report
on Thrombosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1343 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>